- Lobbying
- aventis
Lobbying Arrangements Results for 'Aventis'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Contacts with regard to Miscellaneous Tariff Bills |
sanofi-aventis U.S. Inc.
|
BARNES, RICHARDSON & COLBURN | |||
Details Cardio-vascular & diabetes prevention awareness obesity related congressional caucus congressional health screening |
Sanofi-aventis
Pharmaceutical manufacturer |
Mr. Jon Christensen | |||
Details Australian government policy on intellectual property and its impact on the Australian healthcare system |
Sanofi-Aventis Australia Pty Ltd
|
CapitalHill Advisory | |||
Details TRICARE |
Sanofi-Aventis
|
Hamilton Advisors | |||
Details Medicare Coverage |
SANOFI-AVENTIS
|
KESSLER & ASSOCIATES BUSINESS SERVICES | |||
Details Medicare. |
Sanofi US Services Inc f/k/a sanofi-aventis U.S. Inc.
|
Hogan Lovells US LLP | |||
Details Issues relating to prescription drugs and patent reform |
Sanofi-Aventis
|
STEPTOE & JOHNSON LLP | |||
Details Generic drug approval issues before Congress and the Executive Branch |
Sanofi-Aventis US
Pharmaceutical company |
BROWNSTEIN HYATT FARBER SCHRECK, P.C. | |||
Details Cardio-vascular & diabetes prevention awareness obesity related congressional caucus congressional health screening |
Sanofi-aventis
Pharmaceutical manufacturer |
Mr. Jon Christensen | |||
Details HR 1260, Patent Reform Act of 2009 S. 3686/HR ____, Labor, Health, and Human Services Appropriations Bill for FY2011 |
sanofi-aventis U.S. Inc.
|
Wheat Government Relations | |||
Details Food and Drug Legislation |
Sanofi-Aventis, U.S. LLC
pharmaceutical company |
FOLEY HOAG LLP | |||
Details general perscription drug issues |
Sanofi Aventis
Company that conducts pharmaceutical research and development |
Wheat Government Relations | |||
Details FDA related issues; DTC advertizing follow on biologics-(biosimilars); Health care reform issues as they relate to pharmaceutical industry in general and sanofi-aventis in particular Manufacturing ... |
sanofi-aventis U.S. Inc.
|
PrO Unlimited | |||
Details issues in PPACA, health reform that might impact pharmaceuticals and veterans health care |
Sanofi-Aventis, US, Inc.
|
McKenna Long & Aldridge LLP | |||
Details FDA approval of follow on biologics, including S. 1679 |
Sanofi-Aventis U.S. Inc
|
MCDERMOTT WILL & EMERY LLP | |||
Details Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act. General is... |
Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.)
|
PARRY, ROMANI, DECONCINI & SYMMS | |||
Details Patient Protection and Affordable Care Act - H.R.3590 Affordable Health Care for America Act - HR 3962; Follow-on Biologics - H.R.1427, H.R.1548 |
Sanofi-aventis U.S., Inc.
discover, develops and markets prescription pharmaceuticals |
FOLEY HOAG LLP | |||
Details General issues affecting the pharmaceutical industry. |
sanofi-aventis U.S. Inc.
|
Mr. HERBERT ALLEN "MIKE" AILSWORTH | |||
Details Issues related to corporate tax reform and extension of the R&D tax credit. Issues related to pharmaceutical reimbursement; Issues related to the expansion of Medicaid drug rebate; Issues related t... |
SANOFI-AVENTIS U.S. Inc.
|
RICCHETTI INCORPORATED | |||
Details Issues pertaining to medicare reimbursement |
SANOFI AVENTIS
|
SIDLEY AUSTIN LLP | |||
Details Pandemic influenza, biodefense, and other vaccine-related issues. |
sanofi pasteur
Vaccine production |
DLA Piper Rudnick Gray Cary US LLP | |||
Details Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation," a strengthened and permanent U.S. R&D tax credit, inclu... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
CANFIELD & ASSOCIATES, INC. | |||
Details General reprensentation on health issues relating to chronic disease such as diabetes, cancer, vascular and cardiovascular disease related conditions in the Labor HHS Appropriations bill. |
Sanofi Aventis U.S. Inc
|
Cornerstone Government Affairs, LLC | |||
Details H. Res 295 and S. Res 243 - Resolution to promote increased awareness, diagnosis, and treatment of atrial fibrillation, and to address high mortality and morbidity and to reduce hospitalizations. -... |
sanofi-aventis U.S., Inc
Pharmaceutical Company |
Ms. Camille Bonta | |||
Details International taxes - Proposed legislation re this issue. |
sanofi-aventis U.S. Inc.
|
The Duberstein Group Inc. | |||
Details ***, no specific bill(s), Deep Vein Thrombosis awareness |
Sanofi-Aventis
Healthcare/Pharmaceutical |
TARPLIN, DOWNS & YOUNG, LLC | |||
Details Issues related to onshoring biopharmaceutical manufacturing. |
EuroAPI
|
AKIN GUMP STRAUSS HAUER & FELD | |||
Details Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH fund... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
TCH Group, LLC | |||
Details Education about the necessity and safety of vaccines and their role in preventing childhood disease. Issues related to pharmaceutical pricing in general (no specific legislation) |
Sanofi US Services, Inc. (formerly known as "sanofi-aventis U.S. Inc.)
|
Knight Capitol Consultants | |||
Details Issues related to prescription-to- over the counter switch; issues related to influenza vaccines; issues related to 340B; issues related to Respiratory Syncytial Virus (RSV) access; issues related ... |
Sanofi US Services Inc.
|
in-house lobbying | |||
Details Vaccine and generic biological issues and related appropriation issues, including vaccines for children, pandemic concerns, influenza vaccine issues, stockpile, bioterrorism, bioterrorism counterme... |
SANOFI PASTEUR, INC. (FORMERLY AVENTIS PASTEUR)
|
in-house lobbying | |||
Details vaccine related issues |
Sanofi Pasteur
|
Ogilvy Government Relations | |||
Details FDA drug approval process S.1695-Biologics Price Competition and Innovation Act |
SANOFI-AVENTIS US
|
BROWNSTEIN HYATT FARBER SCHRECK, LLP | |||
Details DOJ policy regarding off label communications. |
Medical Information Working Group
|
SIDLEY AUSTIN LLP | |||
Details Health care reform; drug safety, value and reimbursement; prevention, diagnosis and treatment of chronic disease; implementation of related provisions in the Affordable Care Act; value of prescript... |
Sanofi US Services Inc.
|
Capitol Counsel LLC | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details IRA implementation, transparency, vaccines, coverage and access IRA implementation, supply chain integrity, 340B, orphan drugs, newborn screening, expanded access, transparency, drug shortages, dru... |
Sanofi US Services, Inc. (formerly known as Genzyme Corporation)
|
TARPLIN, DOWNS & YOUNG, LLC |